BioSante's CML vaccine gains orphan-drug status from FDA

06/7/2010 | International Business Times · Reuters

BioSante Pharmaceuticals said its experimental vaccine GVAX CML was granted orphan-drug designation by the FDA for treating patients with chronic myeloid leukemia. The drugmaker previously obtained orphan status for two other GVAX vaccines to treat pancreatic cancer and acute myeloid leukemia.

View Full Article in:

International Business Times · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL